Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Acquired by Walleye Capital LLC

Walleye Capital LLC raised its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 96.4% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 43,899 shares of the biotechnology company’s stock after purchasing an additional 21,550 shares during the period. Walleye Capital LLC owned 0.21% of Enanta Pharmaceuticals worth $455,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC bought a new stake in shares of Enanta Pharmaceuticals during the second quarter valued at approximately $35,000. US Bancorp DE raised its stake in Enanta Pharmaceuticals by 4,933.7% during the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 4,243 shares in the last quarter. Quest Partners LLC boosted its position in Enanta Pharmaceuticals by 511.2% during the 2nd quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock worth $150,000 after acquiring an additional 9,692 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Enanta Pharmaceuticals in the third quarter worth $122,000. Finally, Valence8 US LP acquired a new position in shares of Enanta Pharmaceuticals during the third quarter valued at $207,000. Institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Trading Down 0.1 %

Shares of NASDAQ ENTA opened at $8.00 on Monday. The firm has a 50-day moving average of $10.59 and a two-hundred day moving average of $12.08. The company has a market capitalization of $169.55 million, a price-to-earnings ratio of -1.46 and a beta of 0.49. Enanta Pharmaceuticals, Inc. has a twelve month low of $7.86 and a twelve month high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). The business had revenue of $14.60 million for the quarter, compared to the consensus estimate of $17.99 million. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The company’s quarterly revenue was down 22.8% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.33) earnings per share. As a group, research analysts predict that Enanta Pharmaceuticals, Inc. will post -4.81 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on ENTA shares. HC Wainwright reiterated a “buy” rating and issued a $27.00 target price on shares of Enanta Pharmaceuticals in a research report on Thursday, October 10th. JMP Securities reiterated a “market outperform” rating and issued a $21.00 price objective (down from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. Finally, Robert W. Baird dropped their target price on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $19.50.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.